Aethlon Medical, Inc. (AEMD)

The past six months have seen several events impacting Aethlon Medical, Inc.'s stock price. The company announced its fiscal first-quarter 2026 financial results, reporting an earnings per share (EPS) of -$0.85, which missed analyst expectations. Aethlon Medical effectuated a 1-for-10 reverse stock split. Aethlon reported its fiscal second-quarter 2026 earnings, posting an EPS of -$3.74, significantly missing analysts' expectations. Positive preclinical data was announced showing the Hemopurifier's ability to bind to extracellular vesicles in Long COVID patient samples. A private placement raised approximately $3.3 million in gross proceeds. The company amended warrants to allow for immediate exercise. Aethlon Medical is expected to release its fiscal third-quarter 2026 financial results and host a conference call on February 12, 2026. Over the past year, the stock has experienced a significant decline.

No specific information regarding demand seasonality for Aethlon Medical, Inc.'s products and services was found in the provided search results.

Aethlon Medical, Inc. is a clinical-stage medical therapeutic company focused on developing novel immunotherapeutic devices to address life-threatening diseases. The company's primary product is the Hemopurifier, a clinical-stage therapeutic device designed to combat cancer, eliminate life-threatening viruses, and for use in organ transplantation. Aethlon Medical also provides government contracting services and holds a majority ownership in Exosome Sciences, Inc., which focuses on discovering exosomal biomarkers for neurological disorders.

Aethlon Medical, Inc. is headquartered in San Diego, California, United States. The company's clinical development efforts have a global reach, with ongoing clinical trials for the Hemopurifier in cancer patients with solid tumors in Australia. Aethlon has an open U.S. Food and Drug Administration (FDA) approved Expanded Access Protocol for the treatment of Ebola-infected patients in the U.S. and a corresponding HealthCanada approval in Canada.

Aethlon Medical's brand reputation has been influenced by cautious analyst sentiment and ongoing financial challenges, alongside promising product development. Analysts generally have a "Hold" or "Reduce" consensus rating for the stock. The company has faced significant financial challenges, including reported net losses and ongoing operational deficits. The Hemopurifier holds a U.S. Food and Drug Administration (FDA) "Breakthrough Device" designation. Constructive feedback from clinical sites could lead to quicker data collection and more timely readouts from ongoing studies, which could positively impact reputation. The publication of preclinical data showing the Hemopurifier's ability to bind to extracellular vesicles in Long COVID patient samples also contributes positively to its scientific standing.

Aethlon Medical, Inc.'s ownership is primarily held by insiders and public and other investors, with a smaller percentage by institutional investors. Insiders own approximately 36.06% of the company's stock, while public companies and individual investors hold about 62.61%. Institutional investors own approximately 1.99% of Aethlon Medical's stock. Major individual/insider owners include Family Revocable Trust Ellen R. Weiner, Phillip A. Ward, Angela Rossetti, Richard Tullis, James A. Joyce, and Thomas V. Wornham. Major institutional investors include Armistice Capital LLC, Boothbay Fund Management LLC, Citadel Advisors LLC, Virtu Financial LLC, Sassicaia Capital Advisers LLC, Allegiance Financial Group Advisory Services LLC, and Renaissance Technologies LLC. Danske Bank A/s is also noted as a significant institutional shareholder.